Pulsed Electrical Field Ablation

Pulsed Electrical Field Ablation (PEFA) uses ultra-short electrical pulses to create irreversible non thermalmediated cell death in prostate tumor cells. Unlike heat-based ablation, PEFA is non-thermal—designed to protect nerves, ducts, and sphincter critical to function.

Key Highlights: 1–2 hours in our ambulatory surgery center — no Foley catheter in most cases, no cuts or incisions, and no hospital stay. This is precision, outpatient prostate cancer care designed to preserve urinary and sexual function.

How Pulsed Ablation Works

Step 1 : Identification

Our novel technology identifies cancer on MRI or PET/CT. Our expert surgeons and AI software tools carefully mark cancers not identified by most radiologists.
Step 2: Planning

Our state of the art surgery centers have unique surgical navigation technology. This allows for precise identification of cancer along with targeted destruction. MRI and Ultrasound mapping identify cancer while sparing healthy tissue.
Step 3 : Place

You are comfortably asleep with general anesthesia. Electrodes are positioned transperineally under real-time 3D imaging and specialized surgical navigation. These electrodes are thin (1/19th inch diameter or similar to a sewing needle). This allows for millimeter precision with targeted cell death.
Step 4: Pulse

Electrical energy kills cancer cells while preserving surrounding structures. The ablation maps are reviewed to ensure cancer cell death with preservation of vital structures.
Summary

2 hour total OR time

No cuts or incisions

Non thermal ablation with immune system modulation

Minimal discomfort, controlled with acetaminophen or ibuprofen

Same day discharge

No sexual or urinary side effects

Rapid recovery- most patients resume normal activities in 1-2 days

Future options preserved

Immune mediated

Abscopal Effect

Because PEFA is non-thermal, cancer cell death results in tumor antigen release. This stimulates the immune system and activates cancer fighting T cells. This phenomenon, called the abscopal effect, results in cancer cell death outside of the primary treatment zone. This immune benefit allows for cancer cell death in areas not yet detected- prostate, lymph nodes, or distant sites. This is yet another advantage of non thermal ablation therapy.

Ideal Candidates

Men with localized prostate cancer (often low- to selected intermediate-risk).
Patients who prioritize urinary and sexual function preservation.
Men who want a minimally invasive outpatient treatment.
Those who are not ideal surgical candidates or wish to avoid prolonged recovery.
Select higher-risk or complex cases may be considered after thorough evaluation.